Your browser is no longer supported. Please, upgrade your browser.
Settings
RDUS Radius Health, Inc. daily Stock Chart
RDUS [NASD]
Radius Health, Inc.
Index- P/E- EPS (ttm)-2.77 Insider Own0.50% Shs Outstand46.39M Perf Week-8.65%
Market Cap590.61M Forward P/E- EPS next Y-1.48 Insider Trans36.56% Shs Float46.28M Perf Month-14.26%
Income-127.90M PEG- EPS next Q-0.71 Inst Own- Short Float14.49% Perf Quarter-15.03%
Sales191.40M P/S3.09 EPS this Y40.80% Inst Trans0.47% Short Ratio11.08 Perf Half Y-37.44%
Book/sh-1.60 P/B- EPS next Y37.60% ROA-57.30% Target Price- Perf Year-38.23%
Cash/sh2.84 P/C4.28 EPS next 5Y29.60% ROE363.30% 52W Range10.32 - 29.97 Perf YTD-39.73%
Dividend- P/FCF- EPS past 5Y6.50% ROI-73.20% 52W High-59.33% Beta1.15
Dividend %- Quick Ratio3.00 Sales past 5Y- Gross Margin91.20% 52W Low18.12% ATR0.85
Employees383 Current Ratio3.10 Sales Q/Q60.70% Oper. Margin-55.40% RSI (14)40.23 Volatility7.14% 6.56%
OptionableYes Debt/Eq- EPS Q/Q13.10% Profit Margin-66.80% Rel Volume1.39 Prev Close12.15
ShortableYes LT Debt/Eq- EarningsAug 10 BMO Payout- Avg Volume605.57K Price12.19
Recom2.60 SMA20-6.04% SMA50-7.86% SMA200-30.65% Volume408,002 Change0.33%
Jul-08-20Downgrade SVB Leerink Outperform → Mkt Perform $17
May-13-20Downgrade Morgan Stanley Overweight → Equal-Weight $20
Apr-24-20Initiated Stifel Hold $20
Aug-29-19Upgrade Citigroup Neutral → Buy $24 → $40
May-30-19Resumed Citigroup Neutral
May-29-19Upgrade Goldman Neutral → Buy
Feb-14-19Initiated H.C. Wainwright Neutral $22
Mar-29-18Initiated Leerink Partners Outperform $53
Jan-29-18Initiated Morgan Stanley Overweight $57
Dec-06-17Initiated Citigroup Neutral $30
Oct-06-17Resumed Goldman Neutral
Mar-24-17Reiterated H.C. Wainwright Buy $71 → $66
Sep-21-16Reiterated H.C. Wainwright Buy $55 → $71
Aug-04-16Downgrade Maxim Group Hold → Sell $24
May-23-16Initiated H.C. Wainwright Buy $55
Mar-30-16Initiated Goldman Neutral
Feb-24-16Downgrade Jefferies Buy → Hold
Oct-02-15Initiated JP Morgan Overweight $88
Sep-24-15Reiterated Canaccord Genuity Buy $70 → $85
Aug-14-15Initiated Deutsche Bank Buy $90
Aug-03-20 12:31PM  
Jul-27-20 04:15PM  
Jul-24-20 07:15AM  
Jul-23-20 04:15PM  
Jul-17-20 10:54AM  
Jun-16-20 10:44AM  
Jun-10-20 05:07PM  
Jun-06-20 11:31AM  
May-27-20 05:00AM  
May-08-20 04:46PM  
12:32PM  
May-07-20 04:15PM  
Apr-30-20 12:34PM  
Apr-28-20 04:35PM  
04:30PM  
Apr-20-20 04:15PM  
Apr-08-20 12:13PM  
Mar-28-20 11:30AM  
Mar-03-20 09:15AM  
07:33AM  
Mar-02-20 07:47AM  
Feb-27-20 09:05AM  
07:30AM  
Feb-26-20 08:36AM  
Feb-25-20 11:28AM  
Feb-20-20 12:31PM  
Feb-13-20 04:05PM  
04:05PM  
Jan-22-20 06:36AM  
Jan-13-20 09:00AM  
Jan-09-20 01:30PM  
Jan-06-20 04:14PM  
09:13AM  
Dec-12-19 09:36AM  
Dec-10-19 03:38PM  
Dec-06-19 09:47AM  
Dec-05-19 11:31AM  
Dec-02-19 04:52PM  
Nov-15-19 04:15PM  
Nov-09-19 10:21AM  
Nov-06-19 11:10AM  
Nov-05-19 08:05PM  
04:05PM  
11:23AM  
Oct-29-19 10:33AM  
Oct-27-19 06:42PM  
Oct-24-19 04:34AM  
Oct-23-19 05:37PM  
Sep-13-19 06:03PM  
Sep-09-19 10:48AM  
Sep-06-19 09:31AM  
Sep-03-19 09:00AM  
08:35AM  
Aug-17-19 08:20AM  
Aug-08-19 10:24AM  
09:38AM  
Aug-07-19 06:55PM  
Aug-05-19 04:00PM  
Jul-31-19 10:36AM  
Jul-23-19 09:00AM  
Jul-17-19 04:52PM  
Jul-03-19 01:44PM  
Jun-28-19 09:56AM  
Jun-25-19 09:37AM  
Jun-20-19 03:29PM  
Jun-07-19 09:30AM  
Jun-04-19 09:00AM  
May-16-19 06:59PM  
May-10-19 04:42PM  
01:24AM  
May-09-19 03:30PM  
11:29AM  
May-08-19 08:55AM  
07:56AM  
07:51AM  
May-06-19 08:11AM  
May-01-19 10:32AM  
Apr-26-19 12:37PM  
Apr-23-19 09:00AM  
Apr-18-19 03:38PM  
Apr-17-19 08:00AM  
Apr-16-19 06:54PM  
Apr-10-19 10:16AM  
Mar-30-19 09:30AM  
Mar-29-19 07:45AM  
Mar-23-19 12:45PM  
Mar-18-19 08:00AM  
Mar-11-19 04:30PM  
Mar-08-19 11:03AM  
Mar-01-19 02:18PM  
09:00AM  
Feb-28-19 09:32PM  
04:05PM  
Feb-19-19 09:00AM  
Feb-14-19 09:00AM  
Feb-06-19 07:45AM  
Jan-25-19 09:00AM  
Jan-22-19 10:37AM  
Jan-08-19 04:30PM  
Jan-07-19 09:22AM  
Radius Health, Inc., a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS, an anabolic agent for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in phase 3 clinical study for the treatment of osteoporosis in men; abaloparatide transdermal patch, a short-wear-time patch, that is in phase 3 clinical study to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in phase 3 clinical study for the treatment of hormone receptor-positive breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator, which is in phase 1A clinical study to treat metastatic breast cancer. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Eisai Co. Ltd.; Duke University; and Teijin Limited. Radius Health, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BIOTECH TARGET N V10% OwnerJul 08Buy13.2125,000330,1786,956,685Jul 09 02:40 PM
BIOTECH TARGET N V10% OwnerApr 30Buy15.7550,000787,5556,931,685May 04 05:32 PM
Dere Willard HDirectorFeb 26Sale17.951,92534,55412,195Feb 28 04:15 PM
Kelly Joseph FrancisSr. VP of Sales and MarketingFeb 26Sale17.9388915,94224,111Feb 28 04:15 PM
Carmona JoseChief Financial OfficerFeb 26Sale17.931,29223,16946,708Feb 28 04:15 PM
Rosenberg AnthonyDirectorFeb 26Sale17.951,81532,57912,401Feb 28 04:15 PM
Morris Charles QChief Medical OfficerFeb 26Sale17.931,25622,52433,744Feb 28 04:15 PM
Hughes OwenDirectorFeb 26Sale17.952,75049,36310,650Feb 28 04:15 PM
BIOTECH GROWTH N V10% OwnerNov 06Buy23.00100,0002,300,3006,881,685Nov 08 02:52 PM